Page History

...

1. Where do you show that this challenge assay is done against M. Tuberculosis (or any microbe of interest, like SARS-CoV-2)? - NHOID is not appropriate here because in this case because the subject of study is not the TB bug the M. Tuberculosis itself but whether someone has been previously exposed with TBto M. Tuberculosis. A positive result does not mean the person is currently infected with TB, it may mean that the person had been previously infected by, or vaccinated with TBagainst M. Tuberculosis. NHOID is used when you know the bug or a reference strain is presented present in the testing sample. 
2. CP domain has developed a new standard variable called Test Condition Agent/CNDAGT (CP Specification), which is used to represent stimulating agents, like the values in ASSYAG above, should this variable be added to LB, or IS? 

   Status
   colour Green title Team agrees

   
   
3. Lastly, Interferon-Gamma Response Assay is a classic immunological test, is it correct to map this to the LB domain?
   
   1. Can we model this in the IS domain, see example dataset below. Yes -

      Status
      colour Green title Team Agrees

   2. If we model this test in IS, how do we distinguish it from the INFg test in lab. Can we draw the line where if we are running a routine lab test looking for IFNg levels it goes to LB vs. IFNg challenge/response test toward a specific, known microorganism then it goes to IS? Yes-

      Status
      colour Green title Team Agrees

...

Similarly if we were to model Jozef's request in IS for https://loinc.org/95971-8/ --- SARS CoV-2 stimulated gamma interferon [Presence] in Blood

2